Table 3.

Liquid biopsy results and RR

(a) Association of cfDNA quantification and maxVAF at T1 and T2 with RR
		PR (N = 31)	SD (N = 39)	PD (N = 43)	Total (N = 113)	p value
maxVAF at T1	N	31	39	43	113	<0.001
	Median (Q1, Q3)	1.23 (0.02, 4.40)	0.02 (0.02, 1.34)	4.61 (0.02, 15.02)	1.28 (0.02, 7.65)
maxVAF at T2	N	29	37	39	105	<0.001
	Median (Q1, Q3)	0.02 (0.02, 0.99)	0.02 (0.02, 1.21)	3.81 (1.06, 13.66)	0.99 (0.02, 3.91)
maxVAF at T3	N	29	38	16	83	0.0010
	Median (Q1, Q3)	0.02 (0.02, 0.02)	0.02 (0.02, 1.43)	4.84 (0.02, 10.79)	0.02 (0.02, 1.66)
cfDNA at T1	N	31	39	43	113	<0.001
	Median (Q1, Q3)	8.81 (5.49, 12.34)	8.28 (6.36, 10.90)	13.80 (10.08, 24.34)	9.91 (6.64, 15.21)
cfDNA at T2	N	29	37	39	105	<0.001
	Median (Q1, Q3)	8.50 (4.84, 13.01)	8.22 (5.76, 12.86)	14.97 (10.56, 51.69)	10.81 (6.10, 17.88)
cfDNA at T3	N	29	38	16	83	<0.001
	Median (Q1, Q3)	6.10 (4.99, 8.15)	10.06 (6.59, 12.51)	16.66 (10.71, 32.31)	8.25 (5.30, 13.08)

(b) Impact on PFS of molecular variables performed at the time of radiological assessment (T3) for patients achieving RR (univariate analysis)
		PFS univariate analysis
		n	Events	Median PFS (95% CI)	log-rank	HR (95% CI)	p value
cfDNA at T3	<9.16	43	35	17.5 (10.0; 24.9)	0.0023	Ref
	≥9.16	24	22	7.8 (5.8; 10.4)		2.31 (1.33; 4.01)	0.0029
maxVAF at T3	<0.025	48	39	11.7 (9.8; 17.9)	0.0121	Ref
	≥0.025	19	18	6.8 (5.6; 11.3)		2.04 (1.16; 3.60)	0.0139

(c) Impact on OS of molecular variables performed at the time of radiological assessment (T3) for patients achieving RR (univariate analysis)
		OS univariate analysis
		n	Events	Median (95% CI)	log-rank	HR (95% CI)	p value
cfDNA at T3	<5.27	20	10	35.7 (14.5; NA)	0.0049	Ref
	≥5.27	47	38	19.9 (12.9; 25.8)		2.65 (1.31; 5.36)	0.0066
maxVAF at T3	<0.025	48	32	28.5 (18.5; 37.7)	0.0241	Ref
	≥0.025	19	16	16.3 (10.8; 21.2)		2.19 (1.14; 4.19)	0.0179